How Does CAR-T Therapy’s Efficacy Translate to Clinical Value for Hong Kong Patients with Refractory Hematological Malignancies, and How Can Optimized Manufacturing Help Close the Current Access Gap?. J. Med. Life Sci. 2026;2(1):53-70. doi:10.71222/dt007s28